Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats

European Journal of Pharmacology

Volumn 591, Issue 1-3, 2008, Pages 224-230

  Martinez, Marcio L L ^a   Castro, Michele M ^a   Rizzi, Elen ^a   Fernandes, Karla ^a   Demacq, Caroline ^a   Bendhack, Lusiane M ^a   Gerlach, Raquel F ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

2K 1C hypertension; Metalloproteinase; Oxidative stress; Renovascular hypertension; Vascular dysfunction

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DRUG VEHICLE; GELATINASE A; LERCANIDIPINE; MESSENGER RNA; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; ATTENUATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FLUOROMETRY; HYPERTENSION; MALE; MORPHOMETRICS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENOVASCULAR HYPERTENSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; VASCULAR RING; VASODILATATION; ZYMOGRAPHY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; ENZYME PRECURSORS; GELATINASES; HYPERTENSION, RENOVASCULAR; MALE; MATRIX METALLOPROTEINASE 2; OXIDATIVE STRESS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIOBARBITURIC ACID REACTIVE SUBSTANCES; VASODILATION;

EID: 48749128063     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.096     Document Type: Article

References (41)

1. Arribas S.M., Hinek A., and Gonzalez M.C. Elastic fibres and vascular structure in hypertension. Pharmacol. Ther. 111 (2006) 771-791
2. Asanuma K., Magid R., Johnson C., Nerem R.M., Galis Z.S., O'Callaghan C.J., and Williams B. Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells. Am. J. Physiol., Heart Circ. Physiol. 284 (2003) H1778-1784
3. Borghi C. Lercanidipine in hypertension. Vasc. Health Risk Manage. 1 (2005) 173-182
4. Bouvet C., Gilbert L.A., Girardot D., deBlois D., and Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 45 (2005) 432-437
5. Castro M.M., Rizzi E., Rascado R.R., Nagassaki S., Bendhack L.M., and Tanus-Santos J.E. Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur. J. Pharmacol. 498 (2004) 189-194
6. Castro M.M., Rizzi E., Figueiredo-Lopes L., Fernandes K., Bendhack L.M., Pitol D.L., Gerlach R.F., and Tanus-Santos J.E. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198 (2008) 320-331
7. Cau S.B., Dias-Junior C.A., Montenegro M.F., de Nucci G., Antunes E., and Tanus-Santos J.E. Dose-dependent beneficial hemodynamic effects of BAY 41-2272 in a canine model of acute pulmonary thromboembolism. Eur. J. Pharmacol. 581 (2008) 132-137
8. Chesler N.C., Ku D.N., and Galis Z.S. Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am. J. Physiol. 277 (1999) H2002-2009
9. Cohuet G., and Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol. Ther. 111 (2006) 81-98
10. Cominacini L., Fratta Pasini A., Garbin U., Pastorino A.M., Davoli A., Nava C., Campagnola M., Rossato P., and Lo Cascio V. Antioxidant activity of different dihydropyridines. Biochem. Biophys. Res. Commun. 302 (2003) 679-684
11. Dao H.H., Lemay J., de Champlain J., deBlois D., and Moreau P. Norepinephrine-induced aortic hyperplasia and extracellular matrix deposition are endothelin-dependent. J. Hypertens. 19 (2001) 1965-1973
12. Fernandez-Patron C., Radomski M.W., and Davidge S.T. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ. Res. 85 (1999) 906-911
13. Fernandez-Patron C., Stewart K.G., Zhang Y., Koivunen E., Radomski M.W., and Davidge S.T. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ. Res. 87 (2000) 670-676
14. Flamant M., Placier S., Dubroca C., Esposito B., Lopes I., Chatziantoniou C., Tedgui A., Dussaule J.C., and Lehoux S. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 50 (2007) 212-218
15. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90 (2002) 251-262
16. Gerlach R.F., Uzuelli J.A., Souza-Tarla C.D., and Tanus-Santos J.E. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal. Biochem. 344 (2005) 147-149
17. Gerlach R.F., Demacq C., Jung K., and Tanus-Santos J.E. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin. Biochem. 40 (2007) 119-123
18. Griendling K.K., and FitzGerald G.A. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 108 (2003) 2034-2040
19. Grote K., Flach I., Luchtefeld M., Akin E., Holland S.M., Drexler H., and Schieffer B. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ. Res. 92 (2003) e80-e86
20. Incandela L., Belcaro G., Cesarone M.R., De Sanctis M.T., Griffin M., Cacchio M., Nicolaides A.N., Bucci M., Barsotti A., Martines G., Cornelli U., and Di Renzo A. Oxygen-free radical decrease in hypertensive patients treated with lercanidipine. Int. Angiol. 20 (2001) 136-140
21. Lerman L.O., Chade A.R., Sica V., and Napoli C. Animal models of hypertension: an overview. J. Lab. Clin. Med. 146 (2005) 160-173
22. Martinez A., Oh H.R., Unsworth E.J., Bregonzio C., Saavedra J.M., Stetler-Stevenson W.G., and Cuttitta F. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem. J. 383 (2004) 413-418
23. Martinez M.L., Lopes L.F., Coelho E.B., Nobre F., Rocha J.B., Gerlach R.F., and Tanus-Santos J.E. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J. Cardiovasc. Pharmacol. 47 (2006) 117-122
24. Mason R.P., Marche P., and Hintze T.H. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 2155-2163
25. Moreau P., and Schiffrin E.L. Role of endothelins in animal models of hypertension: focus on cardiovascular protection. Can. J. Physiol. Pharm. 81 (2003) 511-521
26. Nelson K.K., and Melendez J.A. Mitochondrial redox control of matrix metalloproteinases. Free Radic. Biol. Med. 37 (2004) 768-784
27. Prandin M.G., Cicero A.F., Veronesi M., Cosentino E., Dormi A., Strocchi E., and Borghi C. Persistence on treatment and blood pressure control with different first-line antihypertensive treatments: a prospective evaluation. Clin. Exp. Hypertens. 29 (2007) 553-562
28. Ra H.J., and Parks W.C. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 26 (2007) 587-596
29. Rachmani R., Levi Z., Zadok B.S., and Ravid M. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin. Pharmacol. Ther. 72 (2002) 302-307
30. Raffetto J.D., and Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 75 (2008) 346-359
31. Rodrigues G.J., Lunardi C.N., Lima R.G., Santos C.X., Laurindo F.R., da Silva R.S., and Bendhack L.M. Vitamin C improves the effect of a new nitric oxide donor on the vascular smooth muscle from renal hypertensive rats. Nitric Oxide 18 (2008) 176-183
32. Sabbatini M., Vitaioli L., Baldoni E., and Amenta F. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 294 (2000) 948-954
33. Souza-Costa D.C., Zerbini T., Palei A.C., Gerlach R.F., and Tanus-Santos J.E. L-arginine attenuates acute pulmonary embolism-induced increases in lung matrix metalloproteinase-2 and matrix metalloproteinase-9. Chest 128 (2005) 3705-3710
34. Souza-Costa D.C., Figueiredo-Lopes L., Alves-Filho J.C., Semprini M.C., Gerlach R.F., Cunha F.Q., and Tanus-Santos J.E. Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Crit. Care Med. 35 (2007) 239-245
35. Souza-Tarla C.D., Uzuelli J.A., Machado A.A., Gerlach R.F., and Tanus-Santos J.E. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin. Biochem. 38 (2005) 410-414
36. Taddei S., Virdis A., Ghiadoni L., Magagna A., Pasini A.F., Garbin U., Cominacini L., and Salvetti A. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J. Hypertens. 19 (2001) 1379-1386
37. Taddei S., Virdis A., Ghiadoni L., Sudano I., and Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 62 (2002) 265-284
38. Taddei S., Virdis A., Ghiadoni L., Versari D., Salvetti G., Magagna A., and Salvetti A. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 41 (2003) 950-955
39. Watts S.W., Rondelli C., Thakali K., Li X., Uhal B., Pervaiz M.H., Watson R.E., and Fink G.D. Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am. J. Physiol., Heart Circ. Physiol. 292 (2007) H2438-2448
40. Yasmin, McEniery C.M., Wallace S., Dakham Z., Pulsalkar P., Maki-Petaja K., Ashby M.J., Cockcroft J.R., and Wilkinson I.B. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 372
41. Yue H., Uzui H., Shimizu H., Nakano A., Mitsuke Y., Ueda T., and Lee J.D. Different effects of calcium channel blockers on matrix metalloproteinase-2 expression in cultured rat cardiac fibroblasts. J. Cardiovasc. Pharmacol. 44 (2004) 223-230